IAP20 ROSE PORTTO 64 APR 2006

Patent IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Merck & Co., Inc.

Int'l Appln.

No.

PCT/US2004/035112

Int'l Date

Filed

20 October 2004 (10/20/2004)

Serial No.:

(To be assigned)

Case No.: 21179Y

Filed

April 4, 2006

For

ENHANCEMENT OF GROWTH HORMONE LEVELS

WITH A DIPEPTIDYL PEPTIDASE IV INHIBITOR AND A GROWTH HORMONE SECRETAGOGUE

Commissioner for Patents

Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR § 1.97**


Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT_

EXPRESS MAIL NO. EVC60608090 I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450.



This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.98(a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application are not enclosed herewith. Copies of the other references that are cited on the attached form PTO-1449 are enclosed herewith.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

L Fric Thies

Reg. No. 35,382

Attorney for Applicant

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-3904

Date: April 4, 2006

P20 Res Color I U 04 APR 4000

Approved for user hands \$73.02.0067 OMB 065A 0031.
SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure statement by Application 1 6 1

		_			Taken and Traceless Office, 0.5 DEFACTIVE OF COMMERCE			
Sub	Substitute for form 1449A/PTO			COMPLETE IF KNOWN				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	(To be assigned) 575047			
				Filing Date				
STATEMENT BY AFFLICANT		First Named Inventor	Hogenhuis					
				Group Art Unit				
	(use as many sheets	as n	ecessary)	Examiner Name				
et	1	of	1	Attorney Docket Number	21179Y			

			U.S. PA	ATENT DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		US 5,939,560		JENKINS et al	08/17/1999
		US 5,536,716		Chen, et al.	07/16/1996
		US 6,699,871		Edmondson, et al.	03/02/2004
	,				
			_		
_					

			FORE	IGN PATENT D	OCUMENTS	• \
	٠		Foreign Patent Docume	nt		Date of Publication of
Examiner Initials*	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
· ·			 			
						
Examiner Signature			/Sriram K	asturi/	Date Considered	08/23/2008

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.